Biotechnology - Pharmaceutical


Current filters:


Popular Filters

176 to 200 of 1004 results

The Medicines Co to acquire ProFibrix but deal hinges on trial results


US drugmaker The Medicines Company (Nasdaq: MDCO) says it has reached agreement to acquire all of the…

BiotechnologyFibrocapsMergers & AcquisitionsPharmaceuticalProFibrixThe Medicines Company

Biotie buys option to acquire Neurelis, and opportunity for epilepsy candidate


Finland-based biotech firm Biotie Therapies (Nasdaq-OMX; BTH1V) says that it has obtained an exclusive…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurelisNeurologicalNRL-1Pharmaceutical

Government programs play huge role in growth of Turkey's health care market; F&S report


Government funding, growth and consolidation of the middle class, and the rise in non-communicable diseases…

BiotechnologyEuropeHealthcareMarkets & MarketingPharmaceuticalPolitics

FDA "Fast Track" for Soligenix' SGX942 for oral mucositis in patients with head and neck cancer


US clinical-stage biopharma firm Soligenix (OTCQB: SNGX) says that its SGX942 development program for…

BiotechnologyNorth AmericaOncologyPharmaceuticalRegulationSGX942Soligenix

Negative late-stage trial results for Sanofi's iniparib and otamixaban


There was disappointing news from French drug major Sanofi (Euronext: SAN) this morning (June 3), as…


Roche's Avastin extends lives of cervical cancer patients; positive in glioblastoma


Data presented from the study, known as GOG240, showed that the addition of Swiss pharma major Roche's…


Merck Serono collaborates with China's BeiGene on second-generation BRAF Inhibitor


Merck Serono, a division of Germany's Merck KGaA (MRK: DE), today (May 31) announced that it has signed…

BeiGeneBeiGene-283BiotechnologyLicensingMerck KGaAMerck SeronoOncologyPharmaceutical

Market access barriers for multinationals, but Argentina still offers attractive pharma opportunities


Several barriers impede market access but the regulatory landscape in Argentina is changing and attractive…

BiotechnologyMarkets & MarketingPatentsPharmaceuticalRegulationSouth America

Melbourne's Life Sciences - another decade in the sun


Despite the Australian city Melbourne's prestigious heritage in scientific medical research dating back…


Oncothyreon and Array collaborate on anti-HER2 compound ARRY-380


US biotech firms Oncothyreon (Nasdaq: ONTY) and Array BioPharma (Nasdaq: ARRY) plan to collaborate on…

Array BioPharmaARRY-380BiotechnologyLicensingOncologyOncothyreonPharmaceuticalResearch

Avastin remains preferred DME therapy, despite Lucentis extended label in USA


Despite the approval of Swiss drug major Roche (ROG: SIX) subsidiary Genentech's Lucentis (ranibizumab…

AvastinBayerBiotechnologyEyleaGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

GSK to boost vaccines business with 250 million-euro buy of Swiss firm Okairos


UK pharma giant GlaxoSmithKline (LSE: GSK) yesterday (May 29) revealed that it has acquired Swiss closely-held…

BiotechnologyGlaxoSmithKlineMergers & AcquisitionsOkairosPharmaceuticalVaccines

RedHill Biopharma views regulatory pathway for RHB-101 in CHF and hypertension


Emerging Israeli biopharma company RedHill Biopharma (TASE: RDHL) says that it recently concluded a positive…

BiotechnologyCardio-vascularCarvedilolLicensingPharmaceuticalRedHill BiopharmaRegulationResearchRHB-101

Amgen and Astellas link up on drugs for unmet medical needs in Japan


World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

Exec appointments at Biogen Idec and Halozyme; Succession plan for Forest Labs


US biotech firm Biogen Idec (Nasdaq: BIIB) announced that Spyros Artavanis-Tsakonas, has been named chief…

Biogen IdecBiotechnologyForest LaboratoriesHalozyme TherapeuticsManagementPharmaceutical

Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux


Australian drug developer Alchemia (ASX: ACL) and Merck Serono, a subsidiary of Germany's Merck KGaA…

AlchemiaBiotechnologyErbituxHA-IrinotecanMerck KGaAMerck SeronoOncologyPharmaceuticalResearch

Baxter and Halozyme's HyQvia approved in European Union


USA-based Baxter International (NYSE: BAX) and Halozyme Therapeutics (Nasdaq: HALO) say that the European…

BaxterBiotechnologyEuropeHalozyme TherapeuticsHyQviaImmunologicalsPharmaceuticalRegulation

Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations


French drug major Sanofi (Euronext: SAN) and US biotech partner Regeneron Pharmaceuticals (Nasdaq: REGN)…

BiotechnologydupilumabPharmaceuticalRegeneronResearchRespiratory and PulmonarySanofi

NICE rejects Avastin for ovarian cancer, but backs Lucentis for RVO


The UK's drugs watchdog the National Institute for Health and Care Excellence (NICE) has this morning…


176 to 200 of 1004 results

Back to top